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In the first year of funding, my human protocol and consent form have approved by Dana-Farber cancer institute IRB previously need to be revised according to the requirements of the U.S. Army regarding to human subjects protection. 
DISCUSSION:
We have developed a vaccine based on the fusions of DC with ovarian cancer cells. The fusion cells express MHC class I and II, costimulatory molecules and tumor-derived peptides. They are well equipped to activate T cells in the right environment We demonstrate that auto-or allo-DC/ovarian cancer fusion cells are potent stimulators of autologous T cells. Both fusion cells induce specific CTL activity and lysis of autologous tumor cells.
In the coming year, we will study on more case of patients for the effective of fusion cell, and also will focus on the fusion cells of ovarian carcinoma cells with HLA-matched or unmatched allogeneic DC. Both fusion cells will be assessed
